Zobrazeno 1 - 10
of 39
pro vyhledávání: ''
Autor:
Kim A. Reiss, Talia Golan, Ronac Mamtani, Naama Halpern, Yu-Xiao Yang, Ofer Margalit, Dan Aderka, Einat Shacham-Shmueli, Bruce J. Giantonio, Ben Boursi
Publikováno v:
European journal of cancer (Oxford, England : 1990). 96
Background The International Duration Evaluation of Adjuvant therapy (IDEA) pooled analysis compared 3 to 6 months of adjuvant chemotherapy for stage III colon cancer. The overarching goal was to reduce chemotherapy-related toxicity, mainly oxaliplat
Autor:
Yoshito Komatsu, Hideaki Bando, Takehiro Takahashi, Kohei Shitara, Kazumasa Fujitani, Atsuo Takashima, Hideki Shimodaira, Kensei Yamaguchi, Norisuke Nakayama, Tomohiro Nishina, Shuichi Hironaka, Mizutomo Azuma, Eiji Oki
Publikováno v:
European journal of cancer (Oxford, England : 1990). 91
Background Nanoparticle albumin-bound (nab)-paclitaxel was developed to improve paclitaxel solubility and does not need premedication to avoid infusion-related reactions associated with solvent-based (sb)-paclitaxel. We conducted a phase II trial to
Autor:
Antonio Irigoyen, Joaquina Martínez Galán, I. Alés, Luis Jesús López Gomez, Manuel Benavides, A. Saenz, Marta Martin, Ma José Gómez Reina, Jose Luis Manzano Mozo, Sara Arevalo, Vega Iranzo, E. Falcó, G. Pulido, Alicia Navajas Hurtado, Antonieta Salud, Ruth Vera, Javier Gallego, Enrique Aranda, A. Pisa, Roberto Pazo-Cid, Olbia Serra, T. García, Carmen Ponce, Fernando Rivera, Eva Ma Fernández Parra, Esther Martínez Ortega
Publikováno v:
EUROPEAN JOURNAL OF CANCER
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Background: Gemcitabine and erlotinib have shown a survival benefit in the first line setting in metastatic pancreatic cancer (mPC). The aim of this study was to assess whether combining capecitabine (C) with gemcitabine + erlotinib (GE) was safe and
Autor:
Kristie A. Blum, Fred Zheng, Nancy L. Bartlett, Jonathan W. Friedberg, Andrei R. Shustov, Kirit M. Ardeshna, Ian W. Flinn, Ann S. LaCasce, Jeffery Skolnik, Christopher R. Flowers, Kenneth S. Thress
Publikováno v:
European journal of cancer (Oxford, England : 1990). 54
Background:DLBCL is an aggressive non-Hodgkins lymphoma. While between 50-60% of all patients can be cured with combination chemo-immunotherapy such as R-CHOP, many patients are either refractory to initial treatment, or relapse following remission.
Autor:
Joo Ern Ang, James Spicer, Martina Uttenreuther-Fischer, F Solca, Rebecca Kristeleit, K Pelling, David Schnell, D. Harris, F Kyle, Karine Pemberton, J.S. de Bono, Sarah Rudman, Aneta Suder
Publikováno v:
Suder, A, Ang, J E, Kyle, F, Harris, D, Rudman, S, Kristeleit, R, Solca, F, Uttenreuther-Fischer, M, Pemberton, K, Pelling, K, Schnell, D, de Bono, J & Spicer, J 2015, ' A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours ', European Journal of Cancer, vol. 51, no. 16, pp. 2275-84 . https://doi.org/10.1016/j.ejca.2015.07.041
BACKGROUND: This phase I study evaluated afatinib, an irreversible ErbB family blocker, plus paclitaxel in patients with advanced solid tumours likely to express human epidermal growth factor receptor (HER1/EGFR) or HER2.METHODS: Oral afatinib was co
Autor:
Catherine Lombard-Bohas, Sébastien Koné, Clarisse Dromain, Eric Baudin, Jean-Yves Scoazec, Céline Lepère, Laetitia Dahan, Jean-François Seitz, Michel Ducreux, Laurence Bitoun, Denis Smith, Dermot O'Toole, Valérie Vilgrain, Emmanuel Mitry
Publikováno v:
European journal of cancer (Oxford, England : 1990). 50(18)
Neuroendocrine tumours are highly vascular neoplasms known to overexpress vascular endothelial growth factor (VEGF) and its receptor. Bevacizumab, an inhibitor of VEGF, was assessed in combination with chemotherapy in pancreatic neuroendocrine tumour
Autor:
Jörg Trojan, Markus Moehler, S. Zimmermann, Annett Maderer, M. Schütz, U. Denzer, D. Wachtlin, C. Sauvigny, A. W. Lohse, S. Schadmand-Fischer, Michael Geissler, M.M. Dollinger, Stefan Kanzler, E. M. Duerr, A.-K. Kaiser, N. Lubomierski, F. Lammert, A. Distelrath, U. Lindig, Matthias P. Ebert, Peter R. Galle, Carl C. Schimanski, Frank T. Kolligs, M. A. Woerns, L. Berie
Publikováno v:
European journal of cancer (Oxford, England : 1990). 50(18)
Background: Since sorafenib has shown activity in different tumour types and gemcitabine regimens improved the outcome for biliary tract cancer (BTC) patients, we evaluated first-line gemcitabine plus sorafenib in a double-blind phase II study. Patie
Autor:
Mark Harrison, Tamas Hickish, David Propper, Ian Chau, Jim Cassidy, Iain R. Macpherson, Helen Finnigan, Timothy Iveson, Hilary Jones, Michael Braun, Hugo Ford, Stephen Falk, Vanessa Potter, Chooi Lee
Publikováno v:
European journal of cancer (Oxford, England : 1990). 50(18)
Purpose: This randomised phase II trial aimed to compare efficacy of the irreversible ErbB family blocker, afatinib, with cetuximab in patients with KRAS wild-type metastatic colorectal adenocarcinoma (mCRC) with progression following oxaliplatin-and
Autor:
Paul Elson, Jorge A. Garcia, Robert Dreicer, Brian I. Rini, Laura S. Wood, Kriti Mittal, Yana G. Najjar
Publikováno v:
European journal of cancer (Oxford, England : 1990). 50(6)
Treatment of metastatic renal cell carcinoma (mRCC) with sunitinib is often associated with toxicity necessitating dose reduction. Maintaining adequate dosing and drug levels are essential for optimising clinical efficacy. Standard sunitinib schedule
Autor:
Heidenreich, A., Bracarda, S., Mason, M., Ozen, H., Sengelov, L., Oort, I.M. van, Papandreou, C., Fossa, S., Hitier, S., Climent, M.A.
Publikováno v:
European Journal of Cancer, 50, 6, pp. 1090-9
European Journal of Cancer, 50, 1090-9
European Journal of Cancer, 50, 1090-9
Contains fulltext : 136762.pdf (Publisher’s version ) (Closed access) BACKGROUND: Cabazitaxel/prednisone has been shown to prolong survival versus mitoxantrone/prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that